JC
JNCE

JBF Capital’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

JBF Capital’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-38,100
Closed -$852K – 96
2018
Q1 		$852K Buy
+38,100
New +$846K 0.13% 42

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JBF Capital's JNCE Position: Q2 2018 in Review

JBF Capital sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2018, closing a stake of 38,100 shares — an estimated $852K sold.

JBF Capital first reported a position in JNCE in Q1 2018 and held it in 1 quarter. The position peaked at $852K in Q1 2018. 83 funds tracked by Wall St. Rank hold JNCE as of Q2 2018.

  • JBF Capital reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • JBF Capital sold 38,100 Jounce Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $852K.
  • JBF Capital first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • JBF Capital's Jounce Therapeutics, Inc. Common Stock position peaked at $852K in Q1 2018.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2018.

Based on JBF Capital's 13F filing for Q2 2018, filed 9 Aug 2018.